Bristol-Myers Squibb Company (BMY) Yield on Cost (YOC): 4.43%
The yield on cost (YOC) for Bristol-Myers Squibb Company (BMY) is 4.43%.
BMY Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
4.43%
Forward Yield on Cost Projections
If you buy BMY today at the current stock price of $56.48 with a yield of 4.43% and dividends continue to grow at the historical rate (1.6% CAGR), your YOC would be:
Current Yield
4.43%
YOC in 3 Years
7.47%
YOC in 5 Years
10.58%
YOC in 10 Years
25.30%
Interactive Yield on Cost Calculator
Project custom investment returns for Bristol-Myers Squibb Company (BMY) based on your custom cost basis.
Starting Yield
4.43%
Ending YOC
5.62%
Year 15 Dividend
$3.18
Cum. Dividends Recd.
$42.71
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $2.50 | — | 4.43% | $0.00 |
| Year 1 | $2.54 | +1.61% | 4.50% | $2.54 |
| Year 2 | $2.58 | +1.61% | 4.57% | $5.12 |
| Year 3 | $2.62 | +1.61% | 4.64% | $7.74 |
| Year 4 | $2.66 | +1.61% | 4.72% | $10.41 |
| Year 5 | $2.71 | +1.61% | 4.79% | $13.12 |
| Year 6 | $2.75 | +1.61% | 4.87% | $15.87 |
| Year 7 | $2.80 | +1.61% | 4.95% | $18.66 |
| Year 8 | $2.84 | +1.61% | 5.03% | $21.50 |
| Year 9 | $2.89 | +1.61% | 5.11% | $24.39 |
| Year 10 | $2.93 | +1.61% | 5.19% | $27.32 |
| Year 11 | $2.98 | +1.61% | 5.28% | $30.30 |
| Year 12 | $3.03 | +1.61% | 5.36% | $33.33 |
| Year 13 | $3.08 | +1.61% | 5.45% | $36.41 |
| Year 14 | $3.13 | +1.61% | 5.54% | $39.54 |
| Year 15 | $3.18 | +1.61% | 5.62% | $42.71 |
Yield on Cost (YOC) Formula
Formula: Yield on Cost = Annual Dividend / Original Purchase Price × 100
Inputs shown in the projection:
- Original purchase price.
- Annual dividend per share at the starting point.
- Assumed annual dividend growth rate.
- Projected annual dividend divided by original purchase price.
Note: Forward projections assume dividends continue to grow at the designated growth rate. Actual dividend payments are declared by corporate boards and are subject to change.
Bristol-Myers Squibb Company Yield on Cost (YOC) Formula & Definition
Yield on Cost shows the dividend yield based on your original purchase price. As dividends grow, your YOC increases even if the market yield stays the same.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bristol-Myers Squibb Company Yield on Cost (YOC) FAQ
- What is the yield on cost (YOC) for Bristol-Myers Squibb Company (BMY)?
- The yield on cost (YOC) for BMY stock is 4.43%.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher S. Boerner